On December 5, 2022 Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, reported that it will host a virtual event to discuss initial data from the safety lead-in portion of the ongoing Phase 2 SELECT-AML-1 clinical trial and to review the unmet need in newly diagnosed, unfit acute myeloid leukemia (AML) (Press release, Syros Pharmaceuticals, DEC 5, 2022, View Source [SID1234624804]). The event will be held on Saturday, December 10, 2022 beginning at 12:00 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will feature presentations by Syros management, who will review the initial SELECT-AML-1 data and plans for the randomized portion of the Phase 2 trial, as well as Daniel Pollyea, M.D., M.S., Associate Professor of Medicine, Clinical Director of Leukemia Services, University of Colorado School of Medicine, who will provide his perspective on the evolving treatment landscape.

Participants can register for the event here. In addition, a live webcast of the presentation will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

Initial data from the SELECT-AML-1 trial will also be presented on Saturday, December 10, 2022 in a poster session at the 64th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting.